Eclipse Regenesis
Menlo Park
About Eclipse Regenesis
Eclipse Regenesis is a development-stage medical device company focused on harnessing the body’s own tissue regeneration capabilities to treat important diseases. Its flagship product, the Eclipse XL1 System™, utilizes distraction enterogenesis in a treatment designed to mechanically stimulate the body to produce new, fully-functional intestinal to address Short Bowel Syndrome (SBS). With the support of more than 15 years of scientific research and the participation of SBS thought leaders from around the world, the Eclipse Regenesis team is passionate about pioneering a restorative therapy for a disease state that has no cure today. The Eclipse XL1 System is an investigational device and is not currently available commercially in any region.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $2.0M
- Last round: Grant (Aug 2022)
- Website: eclipseregenesis.com
- Phone: [email protected]
Industries & Categories
Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/eclipse-regenesis-5481 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.